Human Genome Sciences Inc. exclusively licensed rights from Abgenix Inc. to develop a fully human monoclonal antibody to the CCR5 receptor, for which Abgenix earns an undisclosed milestone payment. (BioWorld Today)
Human Genome Sciences Inc. exclusively licensed rights from Abgenix Inc. to develop a fully human monoclonal antibody to the CCR5 receptor, for which Abgenix earns an undisclosed milestone payment. (BioWorld Today)
In a move that pleased Genzyme General shareholders but not those of one of its units, Genzyme Corp. announced it was gathering its three divisions - Genzyme General, Genzyme Biosurgery and Genzyme Molecular Oncology - under one trading stock, beginning July 1. (BioWorld Today)
In a move that pleased Genzyme General shareholders but not those of one of its units, Genzyme Corp. announced it was gathering its three divisions - Genzyme General, Genzyme Biosurgery and Genzyme Molecular Oncology - under one trading stock, beginning July 1. (BioWorld Today)
Biotechnology oftentimes eases into the wake of U.S. - and global - burgeoning health risks. That wake occasionally allows companies to ride the waves of newfound investor interest. (BioWorld Today)
Biotechnology oftentimes eases into the wake of U.S. - and global - burgeoning health risks. That wake occasionally allows companies to ride the waves of newfound investor interest. (BioWorld Today)
